The global HER-2 negative breast cancer market represents carcinomas that lack overexpression of human epidermal growth factor receptor 2 (HER2). These types of breast cancers account for around 70% of all breast cancer cases. While chemotherapy and radiation have traditionally been used to treat HER-2 negative breast cancer, newer immunotherapies which activate the body's immune system to...